Whole-exome DNA sequence analysis of Brca2 - And Trp53 -deficient mouse mammary gland tumours

Journal of Pathology

Volumn 236, Issue 2, 2015, Pages 186-200

  Francis, Jeffrey C ^a   Melchor, Lorenzo ^a   Campbell, James ^a   Kendrick, Howard ^a   Wei, Wenbin ^a   Armisen Garrido, Javier ^a   Assiotis, Ioannis ^a   Chen, Lina ^a   Kozarewa, Iwanka ^a   Fenwick, Kerry ^a   Swain, Amanda ^a   Smalley, Matthew J ^a,b   Lord, Christopher J ^a   Ashworth, Alan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Brca2; exome sequencing; mammary gland; mouse model

Indexed keywords

DNA; CD244 PROTEIN, MOUSE; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN; NONHISTONE PROTEIN; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; PRR14 PROTEIN, HUMAN; SIK1 PROTEIN, MOUSE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA SEQUENCE; EXOME; GAIN OF FUNCTION MUTATION; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENE IDENTIFICATION; GENE MAPPING; GENETIC ASSOCIATION; GENOME ANALYSIS; HUMAN; HUMAN GENOME; MET GENE; MOUSE; NEXT GENERATION SEQUENCING; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; SOMATIC MUTATION; TRP53 GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE; ANIMAL; DEFICIENCY; DISEASE MODEL; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE INACTIVATION; GENETICS; GERMLINE MUTATION; MISSENSE MUTATION; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD; BREAST NEOPLASMS; CHROMOSOMAL PROTEINS, NON-HISTONE; DISEASE MODELS, ANIMAL; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; FEMALE; GENE KNOCKOUT TECHNIQUES; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, TRANSGENIC; MUTATION, MISSENSE; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, IMMUNOLOGIC; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84929283146     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4517     Document Type: Article

References (66)

1. Antoniou A, Pharoah PD, Narod S, et al., Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130.
2. Jemal A, Siegel R, Ward E, et al., Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
3. TCGA. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
4. TCGA. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
5. Gudmundsdottir K, Ashworth A,. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006; 25: 5864-5874.
6. Moynahan ME, Pierce AJ, Jasin M,. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001; 7: 263-272.
7. Tutt A, Bertwistle D, Valentine J, et al., Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 2001; 20: 4704-4716.
8. Venkitaraman AR,. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science 2014; 343: 1470-1475.
9. Crook T, Brooks LA, Crossland S, et al., p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 1998; 17: 1681-1689.
10. Rhei E, Bogomolniy F, Federici MG, et al., Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res 1998; 58: 3193-3196.
11. Barber LJ, Rosa Rosa JM, Kozarewa I, et al., Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer. PLoS One 2011; 6: e21639.
12. Nik-Zainal S, Alexandrov LB, Wedge DC, et al., Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 149: 979-993.
13. Alexandrov LB, Nik-Zainal S, Wedge DC, et al., Signatures of mutational processes in human cancer. Nature 2013; 500: 415-421.
14. Moynahan ME, Chiu JW, Koller BH, et al., Brca1 controls homology-directed DNA repair. Mol Cell 1999; 4: 511-518.
15. Lord CJ, Ashworth A,. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 2013; 19: 1381-1388.
16. Tuveson DA, Jacks T,. Technologically advanced cancer modeling in mice. Curr Opin Genet Dev 2002; 12: 105-110.
17. Heyer J, Kwong LN, Lowe SW, et al., Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer 2010; 10: 470-480.
18. Sharpless NE, Depinho RA,. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006; 5: 741-754.
19. Evers B, Drost R, Schut E, et al., Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14: 3916-3925.
20. Hay T, Matthews JR, Pietzka L, et al., Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009; 69: 3850-3855.
21. Varela I, Klijn C, Stephens PJ, et al., Somatic structural rearrangements in genetically engineered mouse mammary tumors. Genome Biol 2010; 11: R100.
22. Wartman LD, Larson DE, Xiang Z, et al., Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. J Clin Invest 2011; 121: 1445-1455.
23. Yuan W, Stawiski E, Janakiraman V, et al., Conditional activation of Pik3ca (H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene 2013; 32: 318-326.
24. McFadden DG, Papagiannakopoulos T, Taylor-Weiner A, et al., Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 2014; 156: 1298-1311.
25. Selbert S, Bentley DJ, Melton DW, et al., Efficient BLG-Cre mediated gene deletion in the mammary gland. Transgen Res 1998; 7: 387-396.
26. Jonkers J, Meuwissen R, van der Gulden H, et al., Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001; 29: 418-425.
27. Melchor L, Molyneux G, Mackay A, et al., Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models. J Pathol 2014; 233: 124-137.
28. Li H, Durbin R,. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
29. McKenna A, Hanna M, Banks E, et al., The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
30. Cibulskis K, Lawrence MS, Carter SL, et al., Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013; 31: 213-219.
31. Thorvaldsdottir H, Robinson JT, Mesirov JP,. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 2013; 14: 178-192.
32. Krumm N, Sudmant PH, Ko A, et al., Copy number variation detection and genotyping from exome sequence data. Genome Res 2012; 22: 1525-1532.
33. Li J, Lupat R, Amarasinghe KC, et al., CONTRA: copy number analysis for targeted resequencing. Bioinformatics 2012; 28: 1307-1313.
34. UCSC in silico PCR tool: http://genome.ucsc.edu
35. MGI curated sets of homology: http://www.informatics.jax.org/homology.shtml
36. The Cancer Genome Atlas data portal: https://tcga-data.nci.nih.gov/tcga/
37. Farmer H, McCabe N, Lord CJ, et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
38. Bryant HE, Schultz N, Thomas HD, et al., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917.
39. + T cells. Mol Immunol 2005; 42: 489-494.
40. Kandoth C, McLellan MD, Vandin F, et al., Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333-339.
41. Graveel CR, DeGroot JD, Su Y, et al., Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci USA 2009; 106: 12909-12914.
42. Ponzo MG, Lesurf R, Petkiewicz S, et al., Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA 2009; 106: 12903-12908.
43. Knight JF, Lesurf R, Zhao H, et al., Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proc Natl Acad Sci USA 2013; 110: E1301-1310.
44. Smolen GA, Muir B, Mohapatra G, et al., Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res 2006; 66: 3452-3455.
45. Klijn C, Holstege H, de Ridder J, et al., Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data. Nucleic Acids Res 2008; 36: e13.
46. Liu P, Cheng H, Santiago S, et al., Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med 2011; 17: 1116-1120.
47. Xu K, Usary J, Kousis PC, et al., Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. Cancer Cell 2012; 21: 626-641.
48. Otto B, Gruner K, Heinlein C, et al., Low-grade and high-grade mammary carcinomas in WAP-T transgenic mice are independent entities distinguished by Met expression. Int J Cancer 2013; 132: 1300-1310.
49. Futreal PA, Coin L, Marshall M, et al., A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-183.
50. Ciriello G, Sinha R, Hoadley KA, et al., The molecular diversity of Luminal A breast tumors. Breast Cancer Res Treat 2013; 141: 409-420.
51. Yoon HG, Chan DW, Reynolds AB, et al., N-CoR mediates DNA methylation-dependent repression through a methyl CpG binding protein Kaiso. Mol Cell 2003; 12: 723-734.
52. Fu J, Yoon HG, Qin J, et al., Regulation of P-TEFb elongation complex activity by CDK9 acetylation. Mol Cell Biol 2007; 27: 4641-4651.
53. Barbacid M., ras genes. Annu Rev Biochem 1987; 56: 779-827.
54. Stephens PJ, Tarpey PS, Davies H, et al., The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486: 400-404.
55. Shah SP, Roth A, Goya R, et al., The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486: 395-399.
56. Zhang L, Liu Y, Song F, et al., Functional SNP in the microRNA-367 binding site in the 3′ UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci USA 2011; 108: 13653-13658.
57. Abdul M, Ramlal S, Hoosein N,. Ryanodine receptor expression correlates with tumor grade in breast cancer. Pathol Oncol Res 2008; 14: 157-160.
58. Stephens PJ, Davies HR, Mitani Y, et al., Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest 2013; 123: 2965-2968.
59. An CH, Kim YR, Kim HS, et al., Frameshift mutations of vacuolar protein sorting genes in gastric and colorectal cancers with microsatellite instability. Hum Pathol 2012; 43: 40-47.
60. Thompson BJ, Mathieu J, Sung HH, et al., Tumor suppressor properties of the ESCRT-II complex component Vps25 in Drosophila. Dev Cell 2005; 9: 711-720.
61. Vaccari T, Bilder D,. The Drosophila tumor suppressor vps25 prevents nonautonomous overproliferation by regulating notch trafficking. Dev Cell 2005; 9: 687-698.
62. Chapman JR, Taylor MR, Boulton SJ,. Playing the end game: DNA double-strand break-repair pathway choice. Mol Cell 2012; 47: 497-510.
63. Waters TR, Swann PF,. Thymine-DNA glycosylase and G to A transition mutations at CpG sites. Mutat Res 2000; 462: 137-147.
64. Alexandrov LB, Nik-Zainal S, Wedge DC, et al., Deciphering signatures of mutational processes operative in human cancer. Cell Rep 2013; 3: 246-259.
65. Fong PC, Boss DS, Yap TA, et al., Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
66. Sandhu SK, Schelman WR, Wilding G, et al., The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2013; 14: 882-892.